Eprosartan mesylate
CAS: 144143-96-4
Ref. 3D-FE61516
1g | 484.00 € | ||
2g | 738.00 € | ||
100mg | 136.00 € | ||
250mg | 206.00 € | ||
500mg | 309.00 € |
Product Information
- 2-Thiophenepropanoic acid, α-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (E)-, monomethanesulfonate
- 2-Thiophenepropanoic acid, α-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (αE)-, methanesulfonate (1:1)
- 2-Thiophenepropanoic acid, α-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (αE)-, monomethanesulfonate
- 4-({2-butyl-5-[(1E)-2-carboxy-3-thiophen-2-ylprop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate
- 4-[[2-Butyl-5-(2-Carboxy-3-Thiophen-2-Yl-Prop-1-Enyl)-Imidazol-1-Yl]Methyl]Benzoic Acid Mesylate
- Eprosartan Methanesulfonate
- Skf 108566J
Eprosartan mesylate is an angiotensin II receptor antagonist and a prodrug of eprosartan. It is used in the treatment of hypertension, congestive heart failure, and for the prophylaxis of organ rejection in renal transplantation. This drug has been shown to inhibit the activation of nuclear factor-κB (NF-κB) and the production of inflammatory cytokines such as growth factor-β1 (GF-β1). Eprosartan mesylate has also been shown to have a beneficial effect on experimental models of type 2 diabetes and metabolic disorders. In clinical trials, it was found that losartan had similar effects on lowering blood pressure as eprosartan mesylate, but the combination increased blood pressure more than either agent alone. Eprosartan mesylate should not be taken with drugs that are metabolized by cytochrome P450 enzymes because they may lead to serious adverse effects such
Chemical properties
Technical inquiry about: 3D-FE61516 Eprosartan mesylate
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.